**February 20, 2018**
14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.
Results of the last year have been discussed and summarized. In 2017 we collaborated with seven international pharmaceutical companies in framework of eight projects. Seven pharmaceutical companies began to use Immune Response Template 1.0, a platform for QSP modeling in immunology and immuno-oncology developed by InSysBio. Three research papers have been published in CPT: Pharmacometrics & Systems Pharmacology and Journal of Controlled Release.
We have discussed the progress in ongoing projects such as QSP model of Alzheimer’s Disease (including amyloid beta and tau description), modeling of T cells and CAR-T therapy in oncology, development of QSP modeling software and other projects. This Annual Internal Scientific Meeting was the 11th held by InSysBio.
| ← | November 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
1.
06 Nov 2018 17:27
Investigation of amyloid pathology mechanisms and prediction of clinical trial results using QSP model
InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
1.
26 Nov 2018 14:03
InSysBio updates Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced a release of updated version of Immune Response Template (IRT) online. The main update in new 2.1.0 version is myeloid-derived suppressor cells (MDSCs). Published human in vitro and in vivo data were analyzed to reconstruct monocytic MDSCs (Mo-MDSCs) and granulocytic MDSCs (Gr-MDSCs) life cycles, derive equations and identify parameters.
|
27
|
28
|
29
|
30
| ||
Thank you for your message! We will get back to you shortly.
